Cochrane · systematic review · CD008940
Pharmacotherapies for cannabis dependence
Nielsen, S, Gowing, L, Sabioni, P, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
23
current version
GRADE rated
23
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 5 · 21.7%Low 14 · 60.9%Moderate 4 · 17.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsΔ9‐Tetrahydrocannabinol preparation compared to placebo for cannabis dependence
Population: cannabis dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants abstinent at end of treatment Δ9‐Tetrahydrocannabinol preparation vs placebo | RR 0.98 [0.64, 1.52] | 3 studies · 305 participants | Moderate Downgraded: imprecision |
Participants experiencing adverse effects Δ9‐Tetrahydrocannabinol preparation vs placebo | RR 1.02 [0.89, 1.17] | 3 studies · 318 participants | Moderate Downgraded: imprecision |
Participants withdrawn due to adverse effects Δ9‐Tetrahydrocannabinol preparation vs placebo | RR 2.72 [0.51, 14.59] | 3 studies · 318 participants | Low Downgraded: imprecision, inconsistency |
Completion of scheduled treatment Δ9‐Tetrahydrocannabinol preparation vs placebo | RR 1.1 [0.88, 1.37] | 4 studies · 369 participants | Low Downgraded: imprecision |
Selective serotonin reuptake inhibitor antidepressant compared to placebo for cannabis dependence
Population: cannabis dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants abstinent at end of treatment Selective serotonin reuptake inhibitor antidepressant vs placebo | RR 1.73 [0.61, 4.89] | 2 studies · 128 participants | Low Downgraded: risk of bias, imprecision |
Participants experiencing adverse effects Selective serotonin reuptake inhibitor antidepressant vs placebo | RR 0.76 [0.57, 1.02] | 1 study · 76 participants | Very low Downgraded: risk of bias, imprecision |
Participants withdrawn due to adverse effects Selective serotonin reuptake inhibitor antidepressant vs placebo | RR 1.71 [0.16, 18.04] | 1 study · 76 participants | Very low Downgraded: risk of bias, imprecision |
Completion of scheduled treatment Selective serotonin reuptake inhibitor antidepressant vs placebo | RR 0.79 [0.49, 1.27] | 3 studies · 198 participants | Very low Downgraded: risk of bias, imprecision |
Mixed action antidepressant compared to placebo for cannabis dependence
Population: cannabis dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants abstinent at end of treatment Mixed action antidepressant vs placebo | RR 0.82 [0.12, 5.41] | 2 studies · 179 participants | Low Downgraded: inconsistency |
Participants experiencing adverse effects Mixed action antidepressant vs placebo | RR 0.93 [0.55, 1.55] | 1 study · 76 participants | Low Downgraded: imprecision, inconsistency |
Participants withdrawn due to adverse effects Mixed action antidepressant vs placebo | RR 1.44 [0.11, 18.9] | 2 studies · 179 participants | Low Downgraded: inconsistency |
Completion of scheduled treatment Mixed action antidepressant vs placebo | RR 0.93 [0.71, 1.21] | 2 studies · 169 participants | Low Downgraded: imprecision, inconsistency |
Anticonvulsants and mood stabilisers compared to placebo for cannabis dependence
Population: cannabis dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants abstinent at end of treatment Anticonvulsants and mood stabilisers vs placebo | RR 1.14 [0.64, 2.04] | 2 studies · 48 participants | Very low Downgraded: risk of bias, imprecision |
Participants withdrawn due to adverse effects Anticonvulsants and mood stabilisers vs placebo | RR 3.67 [0.41, 32.69] | 2 studies · 116 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Completion of scheduled treatment Anticonvulsants and mood stabilisers vs placebo | RR 0.66 [0.47, 0.92] | 3 studies · 141 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Buspirone compared to placebo for cannabis dependence
Population: cannabis dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants abstinent at end of treatment Buspirone vs placebo | RR 1.98 [0.62, 6.33] | 1 study · 175 participants | Low Downgraded: imprecision |
Participants experiencing adverse effects Buspirone vs placebo | RR 1.14 [1, 1.29] | 2 studies · 225 participants | Low Downgraded: imprecision |
Participants withdrawn due to adverse effects Buspirone vs placebo | RR 0.63 [0.15, 2.6] | 2 studies · 225 participants | Low Downgraded: imprecision |
Completion of scheduled treatment Buspirone vs placebo | RR 0.96 [0.74, 1.23] | 2 studies · 225 participants | Low Downgraded: imprecision |
N‐acetylcysteine compared to placebo for cannabis dependence
Population: cannabis dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participants abstinent at end of treatment N‐acetylcysteine vs placebo | RR 0.89 [0.59, 1.35] | 1 study · 302 participants | Low Downgraded: imprecision |
Participants experiencing adverse effects N‐acetylcysteine vs placebo | RR 0.94 [0.71, 1.23] | 2 studies · 418 participants | Moderate Downgraded: imprecision |
Participants withdrawn due to adverse effects N‐acetylcysteine vs placebo | RR 3 [0.12, 72.15] | 1 study · 116 participants | Low Downgraded: imprecision |
Completion of scheduled treatment N‐acetylcysteine vs placebo | RR 1.06 [0.93, 1.21] | 2 studies · 418 participants | Moderate Downgraded: imprecision |